RedHill Biopharma initiates Phase III study of RHB-105

theflyonthewall.com

RedHill Biopharma announced that it has initiated the patient screening process in the ERADICATE Hp study - a Phase III clinical study in the U.S. designed to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed Helicobacter pylori (H. pylori) bacterial infection. Initiation of the RHB-105 Phase III clinical study follows the necessary approvals including FDA acceptance of the Company's Investigational New Drug application and Institutional Review Board approval.

Rates

View Comments (0)